TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total language level based on caregiver report
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in total antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in healthy and unhealthy food intake scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Knee Pain at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Range of Motions at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Muscle Strength at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Walking Speed at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Functional Mobility at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers of Hemagglutination inhibition (HAI) Antibody (Ab) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with detectable HAI Ab titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of toolkit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of toolkit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of toolkit assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage finding the platform useful
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expression levels of driver genes in lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of M1 macrophage in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of M2 macrophage in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in sickness-related impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Agreement rate of the IASLC grading system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Change from Baseline in Plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental Plaque Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Gingivitis Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Change from baseline in BCVA (Best Corrected Visual Acuity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in the Intraocular Pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of participants that were able to spontaneously void after surgery completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time of the void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of residual urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Self-EffectivenessEfficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Simulation-Based Learning Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of Adherence to SCI exercise guidelines
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient-perceived voice improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of subjects experiencing AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Overall response rate in patients with PTCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Givinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Givinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of Givinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of FAPI-PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Succeeded in Operating the EyeControl Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Successful Operation of the EyeControl Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Successfully Operating the EyeControl Device Per Attempt Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post Operative Cognitive Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: easy intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Level of Personality Functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Half circumference at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half circumference at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half circumference at 7 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half circumference at 10 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life_change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delirium incidence
Endpoint domain: Mortality/survival
Primary endpoint: Muscle Stiffness and Muscle Tone of sternocleidomastoid muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Electromyographic activity level measurement of sternocleidomastoid muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Developmental Behaviour Checklist (DBC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to confirmation of bidirectional cavotricuspid isthmus block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Device procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of the conjunctival epithelial defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with delayed adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: sleep quality measurement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in anti-leukemia immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of any hospitalization or all-cause mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of any hospitalization or all-cause mortality from 31 to 180 days
Endpoint domain: Mortality/survival
Primary endpoint: proportion of participants with CMV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: proportion of participants with CMV disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage change in Low-density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Depressive Symptom Score Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety Symptoms Score Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Outcome of transcatheter PDA closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients With a Threshold of Percentage Change in F-18 16 Alpha-fluoroestradiol (FES) Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum alveolar concentration of sevoflurane to block the adrenergic response (MAC-BAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary safety
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma linerixibat area under the concentration-time curve (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of linerixibat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Grade 3 or Higher TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Splenic Response Rate (SRR) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: difference of gastric volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Interferon gamma release assay conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Angiographic restenosis of the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Target vessel stroke or death event
Endpoint domain: Mortality/survival
Primary endpoint: Perioperative cardio-cerebrovascular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Pain Intensity after intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline Pain interference after intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Modified Rankin scale score (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevention of grade III-IV acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Electromyography startle response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness Handicap Inventory Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Genotoxic evaluation by the Micronucleus assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genotoxic evaluation by the Comet assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of trained pharmacists dispensing emicizumab
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfaction of community pharmacists following the HEMOPHAR training program
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Professional practices of community pharmacists in dispensing emicizumab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mortality in COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Difference in area under the concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma maximum measured drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Measure of Moral Distress-Health Professionals (MMD-HP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the Rushton Moral Resilience Scale (RMRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SARS-CoV2 anti-spike protein immunoglobulin G
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SARS-CoV2 Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Mechanical Ventilation or Death
Endpoint domain: Mortality/survival
Primary endpoint: Microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in microvascular flow index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ureteric access sheath placement success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean change in accelerometer-derived physical activity from baseline to six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in student-reported personal (emotional) health from baseline to 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in number of school-reported behavioral incidents from baseline to 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of ECMO related thrombotic events
Endpoint domain: Adverse events/effects
Primary endpoint: increase in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Myocardial oxygen consumption assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate variability slopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of iSTRIVE intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of iDOT intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of successful preparations and deliveries of investigational product
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of adverse events attributed to the investigational product
Endpoint domain: Adverse events/effects
Primary endpoint: Preferred healthcare professional for follow-up
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Days alive out-of-hospital to day 30
Endpoint domain: Mortality/survival
Primary endpoint: Prostatic-specific antigen (PSA)-50 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual performance of non-technical skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Calorie Count from Snacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Hospital Anxiety and Depression Scale (HADS) total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction With Time to Receive Result
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in cardiorespiratory fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients who developed Steroid-induced diabetes mellitus
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression of haemodynamic aortic valve disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscular strength and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Psycho-social wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sequencing and analysis of blood peripheral immune populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sequencing and analysis of intestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sequencing and analysis of urinary microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants who Complete Exercise Program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants who Adhere to Intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Gene expression of circulating endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants to Receive at Least One Cycle of Maintenance Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Progression to severe/critical COVID-19 or death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of paresthesia in hand or lower arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients who normalise their IGT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Number of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in blood eosinophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radiographic recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: echocardiogram order rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cardiologist consult order rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: provider decision-making
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Anxiety levels measured by STAI-Y
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in oral microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life in Neurological Disorders
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Migraine burden
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: change in participants UPCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cutaneous Disease Activity Severity Index (CDASI) activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Youth Report of Internalizing Problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Youth Report of Externalizing Problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline to week 12 in corneal fluorescein staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline to week 12 in eye dryness score (EDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline to week 12 in ocular surface disease index (OSDI) questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Study Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Enrollment and Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Resting Systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tear Breakup time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total work load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intestinal microbiota diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Southampton Hand Assessment Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of the Weekly Sputum Log10 Colony Forming Units Per Millilitre (CFU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: neurological evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: evaluation of physiological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of heel raises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Perinatal Depression Symptomology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Freedom from major device/procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Optic nerve sheath diameter change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Internal jugular vein collapsibility index (IJV-CI) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum diameter of internal jugular vein (Dmax) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes